Regulation of tumoral PD-L1 expression is critical to advancing our understanding of tumor
immune evasion and the improvement of existing antitumor immunotherapies. Herein, we …

The ubiquitin-specific peptidase Ataxin-3 (ATXN3) has emerged as a potential oncogene in
a variety of human cancers. However, the molecular mechanisms underlying how ATXN3 …

Machado-Joseph disease (MJD) is a devastating and incurable neurodegenerative disease
characterised by progressive ataxia, difficulty speaking and swallowing. Consequently …

Background Pancreatic cancer is a common digestive system cancer and one of the most
lethal malignancies worldwide. Ataxin-3 (ATXN3) protein is a deubiquitinating enzyme …

Thyroid cancer is the most common malignant tumor of the endocrine system, and evidence
suggests that post-translational modifications (PTMs) and epigenetic alterations play an …

The high-grade astrocytoma, glioblastoma multiforme (GBM), is the most common primary
tumour of the brain, known for being aggressive and developing drug resistance. The non …

Background Clear cell renal cell carcinoma (ccRCC) is a dominant subtype of kidney cancer
with a dismal outcome at advanced stages. Ataxin 3 (ATXN3) has been proven to play a …

Recent progress has led to nucleotide-based gene silencing strategies as a potential
therapy for spinocerebellar ataxia type 3 (SCA3) and other hereditary ataxias. But recent …

Hepatocellular carcinoma (HCC) is one of the most common gastrointestinal malignancies. It
is not easy to be diagnosed in the early stage and is prone to relapse, with a very poor …